ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments
![](https://exevir.com/wp-content/uploads/2021/07/vuistje.jpg)
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to utilize the fill and finish capabilities for ExeVir’s innovative therapies at Mithra’s integrated R&D and manufacturing platform, Mithra CDMO.
ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern
![](https://exevir.com/wp-content/uploads/2021/07/VAriants-of-concern-1024x619.jpg)
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has generated data on its COVID-19 antibody XVR011 which demonstrate in vitro neutralization activity against SARS-CoV-2 Variants of Concern Gamma and Delta. The company has also obtained grant funding of €3 million from the Flanders Agency for Innovation & Entrepreneurship (VLAIO) to accelerate clinical development of lead asset, the unique llama-derived VHH72-Fc antibody XVR011.